Home › Funds › Redmile Group, LLC › BMRN
Redmile Group, LLC position in BMRN
BIOMARIN PHARMACEUTICAL INC COM · Health Care
Redmile Group, LLC reported holding 265,169 shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM) in its Q2 2026 13F filing — a position valued at US$15.2M, representing 1.02% of its reported portfolio and ranking #22 among its reported holdings. Redmile Group, LLC has disclosed BMRN holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Redmile Group, LLC's BMRN position evolved
Redmile Group, LLC first disclosed a stake in BMRN in Q1 2026 at 173,859 shares (US$9.8M). The position peaked in Q2 2026 at 265,169 shares, worth US$15.2M. Across 2 filings, Redmile Group, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 265,169 shares valued at US$15.2M — an increase of 91,310 shares quarter over quarter.. Notable position changes include a 53% increase in Q2 2026 (shares rose 5% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 173.86K | $9.82M | New |
| Q2 2026 | 265.17K | $15.17M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BMRN and 13F data
BMRN (BIOMARIN PHARMACEUTICAL INC COM) is a Health Care company. 27 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$812.0M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BMRN
- PRIMECAP MANAGEMENT CO/CA/ 14.19M sh · $811.96M · Q2 2026
- Viking Global Investors 7.62M sh · $435.82M · Q2 2026
- VIKING GLOBAL INVESTORS LP 7.62M sh · $435.82M · Q2 2026
- Vestal Point Capital, LP 6.03M sh · $344.75M · Q2 2026
- Deep Track Capital, LP 3.31M sh · $189.25M · Q2 2026
- TENOR CAPITAL MANAGEMENT Co., L.P. 111.50M sh · $108.89M · Q2 2026
More on Redmile Group, LLC
FAQ
How long has Redmile Group, LLC held BMRN?
Redmile Group, LLC has disclosed BMRN holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Redmile Group, LLC's current position in BMRN?
As of Q2 2026, Redmile Group, LLC holds 265.17K shares of BMRN (BIOMARIN PHARMACEUTICAL INC COM), valued at $15.17M, representing 1.02% of its reported portfolio and ranking #22.
Has Redmile Group, LLC been buying or selling BMRN?
In the latest 13F filing (Q2 2026), Redmile Group, LLC increased its position in BMRN. The position peaked in Q2 2026 at 265.17K shares.
Which other funds hold BMRN?
Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.